ZLAB Stock Overview
Develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ZLAB from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Zai Lab Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$26.05 |
| 52 Week High | US$36.60 |
| 52 Week Low | US$13.48 |
| Beta | 1 |
| 1 Month Change | -2.51% |
| 3 Month Change | -9.99% |
| 1 Year Change | 13.21% |
| 3 Year Change | -45.89% |
| 5 Year Change | -52.90% |
| Change since IPO | 44.72% |
Recent News & Updates
Investors Don't See Light At End Of Zai Lab Limited's (NASDAQ:ZLAB) Tunnel
Jan 20
Zai Lab: Rapidly Improving Outlook Bodes Well For The Future
Dec 26Recent updates
Investors Don't See Light At End Of Zai Lab Limited's (NASDAQ:ZLAB) Tunnel
Jan 20Zai Lab: Rapidly Improving Outlook Bodes Well For The Future
Dec 26The Zai Lab Limited (NASDAQ:ZLAB) Third-Quarter Results Are Out And Analysts Have Published New Forecasts
Nov 15Zai Lab Limited (NASDAQ:ZLAB) Stock Catapults 26% Though Its Price And Business Still Lag The Industry
Sep 28Zai Lab (NASDAQ:ZLAB) Has Debt But No Earnings; Should You Worry?
Sep 23Shareholders May Not Be So Generous With Zai Lab Limited's (NASDAQ:ZLAB) CEO Compensation And Here's Why
Jun 12Improved Revenues Required Before Zai Lab Limited (NASDAQ:ZLAB) Stock's 50% Jump Looks Justified
May 14A Risky Bet: Zai Lab's Uncertain Future
Apr 16Lacklustre Performance Is Driving Zai Lab Limited's (NASDAQ:ZLAB) 29% Price Drop
Mar 29We're Hopeful That Zai Lab (NASDAQ:ZLAB) Will Use Its Cash Wisely
Mar 24Why Investors Shouldn't Be Surprised By Zai Lab Limited's (NASDAQ:ZLAB) Low P/S
Jan 18Here's Why We're Not Too Worried About Zai Lab's (NASDAQ:ZLAB) Cash Burn Situation
Sep 22Zai Lab Limited's (NASDAQ:ZLAB) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Jun 24We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth
Jun 02Is Zai Lab Limited (NASDAQ:ZLAB) Trading At A 44% Discount?
Feb 16Zai Lab (NASDAQ:ZLAB) Is In A Good Position To Deliver On Growth Plans
Jan 20Shareholder Returns
| ZLAB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 7.2% | -0.2% | 3.1% |
| 1Y | 13.2% | -7.2% | 23.7% |
Return vs Industry: ZLAB exceeded the US Biotechs industry which returned -7.2% over the past year.
Return vs Market: ZLAB underperformed the US Market which returned 23.7% over the past year.
Price Volatility
| ZLAB volatility | |
|---|---|
| ZLAB Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 18.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ZLAB has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ZLAB's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 2,175 | Samantha Du | www.zailaboratory.com |
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients.
Zai Lab Limited Fundamentals Summary
| ZLAB fundamental statistics | |
|---|---|
| Market cap | US$2.82b |
| Earnings (TTM) | -US$270.85m |
| Revenue (TTM) | US$355.75m |
7.9x
P/S Ratio-10.4x
P/E RatioIs ZLAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZLAB income statement (TTM) | |
|---|---|
| Revenue | US$355.75m |
| Cost of Revenue | US$395.21m |
| Gross Profit | -US$39.46m |
| Other Expenses | US$231.39m |
| Earnings | -US$270.85m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.50 |
| Gross Margin | -11.09% |
| Net Profit Margin | -76.13% |
| Debt/Equity Ratio | 16.9% |
How did ZLAB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/21 19:04 |
| End of Day Share Price | 2025/01/17 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zai Lab Limited is covered by 29 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Meng | BOCI Research Ltd. |
| Wai Chak Yuen | BOCI Research Ltd. |
| Linda Lu | BOCI Research Ltd. |